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Abstract
Objectives:  Many studies suggest a strong familial component to fibromyalgia (FM).  However, these studies 
have nearly all been confined to individuals with “primary” FM, i.e. FM without any other accompanying 
disorder.  The current 2011-16 criteria for diagnosing FM construct a score using a combination of the 
number of painful body sites and the severity of somatic symptoms (FM-score). We estimated the genetic 
heritability of FM-score across sex and age groups to identify subgroups of individuals with greater 
heritability, which may help in the design of future genetic studies. 
Methods:   We collected data on 26,749 individuals of European ancestry undergoing elective surgery at the 
University of Michigan (Michigan Genomics Initiative study, MGI). We estimated the SNP-based heritability 
of FM-score by age and sex categories using genome-wide association study (GWAS) data and a linear mixed 
model.
Results:  Overall, FM-score had an estimated heritability of 13.9% (SE=2.9%). Estimated FM-score 
heritability was highest in individuals ≤ 50 years of age (23.5%; SE=7.9%) and lowest in individuals >60 
years (7.3%; SE=8.1%). These patterns remained the same when we analyzed FM as a case-control 
phenotype. Even through women had approximately 30% higher average FM-score than males across age 
categories, FM-score heritability did not differ significantly by sex. 
Conclusion: Younger individuals appear to have a much stronger genetic component to the FM-score than 
older individuals. Older individuals may be more likely to have what previously had been called “secondary 
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conditions.
 
Background:  Fibromyalgia (FM) is a symptom complex characterized by widespread pain accompanied by 
somatic symptoms such as fatigue, sleep and memory problems. Nearly all recent research studies of FM have 
focused on what is termed “primary FM”, which is FM without any other identifiable autoimmune or structural 
causes of pain.  However similar symptom complexes are observed in individuals with identifiable causes of 
pain such as autoimmune disorders and chronic diseases.  This form of FM is thought to be more similar to 
animal and human studies of “central sensitization”, where ongoing nociceptive input is required to drive the 
processes of central sensitization, at both the level of the spinal cord and brain 1–6. 
Individuals with primary FM typically begin developing pain in their childhood or teens and are often 
diagnosed with regional pain conditions early in their life before finally being diagnosed with FM. Primary FM 
occurs preferentially in females, is strongly familial, and co-aggregates with other regional pain conditions in 
both individuals and families 7–12.  In contrast to primary FM, pain with identifiable causes can be caused by 
pain-related diseases, such as osteoarthritis, which often occur later in life and less is known about its 
heritability. Understanding the pathogenic differences between FM with or without identifiable causes of pain 
may lead to different treatments for the two forms of FM. For example, central nervous system drugs and 
primary FM therapies may be less effective than identification and treatment of the ongoing nociceptive input 
7,13. 
Candidate gene and genome-wide association studies (GWAS) comparing variant allele frequencies in FM 
cases and controls have been performed but many of the results have been inconsistently noted or replicated 14.  
However, the studies to date have been small in size (N < 1000) and would only have been able to identify 
common genetic variants with very large effects 14,15. 
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pain in much larger samples, although it may not always be possible to differentiate patients with or without 
any identifiable causes of pain given available survey or medical records and the high prevalence of 
individuals with peripheral sources of ongoing nociceptive input. Large studies of quantitative pain phenotypes 
can potentially contribute to the understanding of disease processes.  A multi-site chronic pain (MCP) GWAS 
18 performed using the large-scale UK Biobank data, found 76 independent MCP-associated variants at 39 loci 
and estimated MCP heritability of 10.2%. 
Estimates of disease or trait heritability are of interest because they give a sense of the genetic contribution to 
the measured trait. Heritability has traditionally been estimated from family and twin studies, which require 
intensive participant recruitment. But narrow sense heritability (additive components) can also be estimated 
from cohort or case-control based study GWAS data 19,20. The estimation of heritability from GWAS data is 
based on the idea that if genetics underlie the predisposition to disease, individuals with more similar levels of 
a trait or with a disease will tend to share more alleles than individuals with less similar trait levels or without 
the disorder42. For example, estimates of heritability based on GWAS data in non-familial data range from 
55% to 81% for height 19,21, 23% to 51% for BMI 20,22 and 37% to 50% for depression 23,24. The GWAS-based 
estimates are usually smaller than those estimated from familial data or twin studies, likely because they only 
capture additive effects from the variant classes included in the estimation (narrow sense heritability) 25. 
The genetic contributions to trait level or disease risk can vary by age or sex 26, and these differences can be 
assessed by estimating heritability in subgroups of samples. For example, many physical measures including 
basal metabolic rate, systolic blood pressure,  body mass index and neck pain appear to be more heritable in 
younger individuals 27, potentially because trait differences at younger ages are less driven by environmental 
factors or because the process that causes pain at older ages are different or more diverse from those at younger 
ages.
Our goal is to estimate the heritability of FM and of a continuous measure of FM severity and to ask if 
heritability differs by patient sex and/or age at assessment. To do this, we measured FM severity using patient 
completed 2011 Survey Criteria for FM 28,29 from 26,749 European-ancestry individuals undergoing elective 
surgery from the Michigan Genomics Initiative. Using GWAS data we estimated the heritability of a 
continuous phenotype, FM severity (FM-score), across age categories. We also dichotomized FM scores as a 
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categories. Further, we estimated the genetic correlation of FM score with several psychiatric, personality and 
autoimmune traits using publicly available GWAS summary statistics.  
Methods.  
Participants were prospectively recruited into the Michigan Genomics Initiative (MGI), an institutional 
biorepository at the University of Michigan.  All patients were ≥ 18 years of age and were scheduled to have an 
elective surgery on the day of their recruitment. We excluded patients who did not speak English, were unable 
to provide written informed consent, or were currently imprisoned. We obtained written informed consent from 
all patients for use of their clinical data and DNA for research purposes. This study was approved by the 
University of Michigan IRB (IRB ID HUM00099605).  
Genotyping. We genotyped DNA from blood samples using customized versions of Illumina 
HumanCoreExome v12.1 array and applied quality control filters (See Supplementary Section A and B). 
After sample quality control, 37,412 samples remained with 462,868 polymorphic variants. Average 
genotyping rate of the included samples and variants was 99.96%. 
We projected the genotype data for the 37,412 samples on the principal components of Human Genome 
diversity project (HGDP) data using TRACE 30 to infer the genetic ancestry of the samples. Of these samples, 
31,730 (84.8%) individuals were inferred to be of European ancestry. We estimated the sample kinship 31 and 
retained 30,431 samples who had less than a second-degree relationship. We next performed principal 
component analysis on their genotype data. We excluded 33 samples who were outliers based on the first and 
second principal components resulting in 30,398 samples with genotype data. (See Supplementary Section C 
and Supplementary Figure 1). 
Phenotyping. We phenotyped patients preoperatively using a self-report questionnaire of widespread pain and 
psychological status, based on the American College of Rheumatology (ACR) survey criteria for FM. These 
criteria for FM, conceptualized in 2011, represent a validated self-report measure based on presence of 
widespread pain and comorbid symptoms 28,29. To calculate the Widespread Pain Index (WPI), we assessed 19 
specific body areas using the Michigan Body Map (score 0–19) as described in the ACR survey criteria 29. To 
calculate Symptoms Severity Index (SSI) we used the comorbid Symptom Severity scale with questions on 
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and headache (score 0–12). Following Wolfe et al 29 we summed the WPI and SSI to create FM scores 
(potential range 0 to 31).
To dichotomize patients as FM-cases or controls based on FM-score and its components, we used two 
definitions, 
1. FM-2011: any individual with FM-score ≥ 13 was defined as a FM-Criteria2011 case 
2. FM-2016-modified: any individual with 4 of the 5 main body regions having pain and WPI-score ≥ 7 
and SSI-score ≥ 5 or WPI-score 4–6 and SSI-score ≥ 9. 
FM-2016-modified is a modified version of the criteria outlined by Wolfe et al 32 in 2016, adapted to our study 
according to the availability of data (See Supplementary Section D for details).  All individuals not defined as 
a case were defined as controls. 
 Of 30,398 European ancestry individuals with genotype data, 3,649 (12.0%) did not have an FM score (WPI 
was missing for 2,708 (8.9%) and SSI was missing for 3,494 (11.5%) individuals), leaving 26,749 individuals 
for analysis.
Log transformation of FM, WPI and SSI. 
Since the distribution of FM was highly skewed, we added a small constant (0.1) to the FM score to retain 
individuals with a value of zero in the analysis, and log transformed the adjusted score. We regressed the log-
transformed FM (Log-FM) score on the age, age2 and sex using a linear regression model and inverse 
normalized the residuals (inverse normalized FM score). The same transformations were applied to WPI and 
SSI. 
Estimation of heritability and genetic correlation.  The genetic contribution to a phenotype can be measured 
by heritability, the fraction of trait variation explained by genetic variation. We estimated heritability of FM-
score, WPI and SSI using a linear mixed effect model (LMM) 33. 
y = Xβy + gy +  εy
where   is the vector of phenotype values for n individuals, in this case the inverse normalized FM-score (or y
inverse normalized WPI/SSI score);  is a matrix of non-genetic covariates containing the top 10 genetic X
principal components and a binary variable with levels 0 and 1 indicating the genotype array 
(UM_HUNT_Biobank or UM_HUNT_Biobank_v1-1);  is the vector of corresponding fixed effects;  is a βy gy
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genetic relatedness matrix (GRM) between the pairs of individuals (See Supplementary Section E for the 
construction of GRM);  is the genetic variability contributed by the genetic relatedness of the samples;  σy2 εy
 and  is the residual variance of the model. The heritability of the phenotype  is estimated  ∽  N(0,σey2 I) σey2 y
as . We used Genome-wide Complex Trait Analysis (GCTA) 34 to fit this model and estimate the h
2
=  
σy2σy2 +  σey2
heritabilities. We further used a likelihood-ratio-test (LRT) to evaluate the significance of the estimated 
heritability. We note here that  used here is a narrow sense measure of heritability. Thus only measures ℎ2 ℎ2 
the fraction of variability in trait explained by the additive effects of the variants in the array which is lower 
than the total trait heritability.  For a case-control phenotype (binary), we use the same linear mixed model but 
with liability scale adjusting for ascertainment probabilities of the cases by the population prevalence 35. Here, 
we have used two different ways to dichotomize the individuals with FM-score into cases and controls. For 
both the case-control definitions to estimate the heritability of FM as a case-control phenotype we used a 
population prevalence of 2% 36.
The genetic overlap between two phenotypes  and  can be measured by the genetic correlation 20. We y w
estimated the genetic correlation among FM-score, SSI, WPI using multiple linear mixed model. For 
phenotype, , we used the same mixed model (LMM) as for :   w y
w = Xβw + gw +  εw ;  gw ∼  N(0, σw2 K);     εw ∼  N(0,σew2 I) 
with the additional assumption , where   is defined as the co-heritability between the cov(gy,gw) =  σyw K σyw 
phenotypes  and . The genetic correlation between the phenotypes is then defined as . We used y w ryw =  
σ ywσ y σ w
Phenix 37 to fit the model and calculate the co-heritability and subsequently estimated the genetic correlations. 
Further, we estimated the genetic correlation of FM score with selected traits using publicly available summary 
statistics from existing genetic association studies using LD score regression38–40. 
Results  
We included in our analysis 26,749 European ancestry patients who were scheduled for elective surgery. These 
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scores for 26,749 individuals is shown in Figure 1. 10.8% of the sample reported FM score of 0 (both the WPI 
and SSI scores equal 0) (see Supplementary Figure 2 for WPI and SSI distributions). 
FM scores by age categories and by sex are shown in Figure 2. When divided into age subcategories of 10 
years, the age categories 40-50 and 50-60 had significantly higher FM-scores compared to the age category ≤ 
40 and the age categories 60-70, 70-80 and 80-90 had lower FM-score compared to the age category ≤ 40 
(Figure 2A). This pattern was consistent for females and males (Figure 2B and C) (for regression estimates 
see Supplementary Table 1).  In the total sample, the average FM score (mean ± SD) was higher in females 
than in males (6.2 ± 4.9 versus 4.6 ± 4.2 respectively, mean female FM score / mean male FM score = 1.34) 
(see Supplementary Table 2 for the FM scores for patients dichotomized at 50 years).
We asked if the components of FM score, measurements of pain at different sites of the body (WPI) and 
symptoms of pain (SSI) had consistent trends across age and sex (Supplementary Table 3).  Younger (age ≤ 
50) individuals had a lower WPI-score than the older (age > 50) individuals (1.8 ± 2.6 versus 2.0 ± 2.6 
respectively). In contrast, younger individuals had a higher SSI-score than the older individuals (3.8 ± 2.9 
versus 3.4 ± 2.8) (Supplementary Table 3). Females had higher WPI and SSI scores than males (2.1 ± 2.8 
versus 1.6 ± 2.3 respectively for WPI and 4.1 ± 2.9 versus 3.0 ± 2.6 for SI).  
To evaluate the significance of age and sex on FM-score related measures, we used a multiple linear regression 
model simultaneously adjusting for age, age2 and sex. We found that age, age2 and sex were significantly 
associated with FM, WPI and SSI (p-value<0.05) (Supplementary Table 4). To determine if the effect of age 
(younger or older) on FM score varied by sex or the effect of sex on FM score varied by age category (younger 
or older), we tested for an interaction between age category and sex. We did not find significant evidence that 
the effect of sex varied between older and younger individuals or that the effect of age varied between sex.
To estimate the genetic contribution to FM score, we calculated the genotype-based heritability of the inverse 
normalized FM score. We constructed the GRM using the common variants (minor allele frequency > 5%) and 
fit a linear mixed model (See Methods). Estimated FM score heritability was 14% (SD = 2.9; p-value= 1.59 x 
10-7). To examine if the heritability differed by age, we divided the sample into 10-year age categories. Patients 
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the lowest heritability, estimated at 3%, although no age category was significantly heritable on its own. We 
saw similar trends for WPI and SSI (Figure 3).
To obtain larger age subgroups, we dichotomized patients by age cut-offs and estimated the heritability in the 
corresponding age groups (Table 1). For each age cut-off we observed that younger individuals had 
consistently higher heritability of FM score than older individuals. For example, individuals with age ≤ 50 
years had an estimated heritability of 23% (SD = 7.9; p-value =3.0 x 10-4) and those with age > 50 had an 
estimated heritability of 9% (SD = 5.6; p-value = 0.12). This means that the estimated heritability of FM for 
individuals ≤ 50 years is significantly higher than 0. Conversely, the heritability for individuals > 50 years is 
low and could not be distinguished from 0 in this sample. 
When we repeated the analysis by age category separately for males and females, we found that females had 
slightly higher estimated heritabilities than males in almost all age categories. However, we found no evidence 
of a significant difference in the estimated heritabilities between males and females (Supplementary Section 
F, Supplementary Table 5). 
To assess the heritability in individuals more likely to have FM we used the two definitions of FM cases, 1) 
any individual with FM-score ≥ 13 was defined as a FM-2011 case21 (Number of cases= 2,304; sample 
prevalence = 8.2%) and 2) any individual with 4 of the 5 main body regions having pain and WPI-score ≥ 7 
and SSI-score ≥ 5 or WPI-score 4–6 and SSI-score ≥ 9 defined as a FM-2016-modified case (Number of 
cases= 1,319; sample prevalence = 4.9%) (adapted from Wolfe et al 2016). All individuals not defined as a 
case were defined as controls. All but 48 of the FM-2016-modified cases were also defined as FM-2011 cases. 
We estimated heritabilities as 8.6% (p-value=0.005) for FM-2011 and 7.9% (p-value =0.41) for FM-2016-
modified. When divided into age categories, we observed higher estimated heritability for younger individuals 
compared to older individuals, suggesting that the overall trends by age held true in the data across FMness 
measured by different criteria (Supplementary Table 6A and 6B).  
To understand the contributions of the WPI and SSI to the age-based FM score heritability trends, we 
estimated the genetic correlations of FM score with WPI and SSI by 10-year age categories (Figure 4). The 
estimated FM score-WPI genetic correlation varied from 38% for the younger individuals (age ≤ 40), to 66% 
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and ≤ 70). The FM score-SSI genetic correlation varied from 57% in individuals with age ≤ 40 to 88% in 
individuals with age > 60 and ≤ 70. The estimated genetic correlation between WPI and SSI varied between 
55% for the individuals with age > 40 and ≤ 50 to 6% for the older individuals (age > 60 and ≤ 70). These 
genetic correlation estimates show that for younger individuals, both WPI and SSI contribute substantially 
towards the genetic components of FM, while in the older individuals SSI appears to be the dominant 
component. Further, our estimates show that, for younger individuals, WPI and SSI have a substantial shared 
genetic component, while in older individuals, they have a low genetic correlation. Using FM-2011 and FM-
2016-modified definitions to dichotomize individuals to cases and controls, we found similar patterns of 
genetic correlations across age categories (Supplementary Figure 3).
We next tested for co-heritability of FM score with traits that might a priori be expected to be correlated with 
FM score or were found to be significant in the UK Biobank study of multi-site chronic pain (MCP). FM score 
had a significant genetic correlation with psychiatric disorders such as ADHD, neuroticism, major depressive 
symptoms, subjective well-being and depressive symptoms (-0.26 to 0.78; Table 2). We also found significant 
genetic correlation of FM score with immune and autoimmune diseases like asthma and rheumatoid arthritis 
(0.31 to 0.35; Table 2). To understand the contribution of SSI and WPI to the genetic correlations of FM score, 
we separately estimated their genetic correlations with the same traits. For almost all tested traits, SSI had 
similar estimated genetic correlations as FM score. WPI had similar estimated genetic correlations as FM score 
for asthma and rheumatoid arthritis, and of the tested traits, these two were the most strongly genetically 
correlated with WPI. In contrast, WPI showed much lower genetic correlation with psychiatric traits (-0.12 and 
0.19) than we found for FM score or SSI, although nominal significance for genetic correlation of WPI with 
ADHD and neuroticism in younger individuals.  Multiple phenotypes that were reported to have significant 
genetic correlation with MCP in the UK Biobank study did not have significant genetic correlation with FM 
score, WPI or SSI. However, the directions of genetic correlations for these traits were highly consistent 
between the UK Biobank and our sample (9 out of the 10 reported traits in Table 2 had the same direction of 
effects). Further, the estimated genetic correlations for these traits were highly correlated (r > 0.9) to those 
estimated in UK Biobank sample for MCP. 
We also estimated the genetic correlation of FM score, WPI and SSI with the UK Biobank MCP. We found 
significant genetic correlations of MCP with FM-score (0.46), WPI (0.38) and SSI (0.29). For younger 
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Conclusions  
The present study is the largest to date to examine the genetic contributions to the FM-score (a composite 
measure of WPI and SSI). We found that FM score is more heritable in younger than in older individuals 
within this hospital-based sample. Thus, the variability in FM score for younger individuals, which is 
potentially more likely to be primary FM, appears to be more driven by genetic factors shared across 
individuals than in older individuals. Older individuals may have a greater contribution of environmental 
factors to pain, a greater diversity of conditions that increase pain, and/or more susceptibility towards 
nociceptive pain. 
We found that there is a substantial genetic correlation of FM with both WPI and SSI for younger individuals, 
indicating that both the pain component (WPI) and the comorbid symptoms component (SSI) jointly contribute 
to the genetic architecture of FM for the younger individuals. In contrast, for the older individuals, the 
heritability of FM is more highly correlated with comorbid (SSI) component than with the pain (WPI) 
component. Overall, our results suggest that genetic studies of FM might have differing results dependent on 
the age of the participants.
If FM in younger individuals stayed constant throughout their lives one would expect FM measures to slowly 
increase with age as pain from chronic diseases increases, but in this study, we see that the mean FM score (in 
individuals undergoing elective surgery) is slightly lower in older individuals with age.  Other studies have 
shown that the incidence and prevalence of FM wanes over time.  Wolfe et. al. 36 showed that the prevalence of 
chronic widespread pain in Kansas peaked at age 60-69 and then decreased in older individuals. Vincent et. al. 
41 used the 2011 FM Survey criteria to show a prevalence of FM in the general Minnesota population at 8.4% 
for ages 21-39, 6.0% for ages 40-59, and 3.8% for individuals over age 6026. 
Given an individual’s genetic information is constant from birth until death (notwithstanding epigenetic 
modifications), our results suggest that, for a set number of FM cases, inclusion of younger individuals might 
increase the power to detect primary FM. All previous GWAS or large candidate gene studies in FM were 
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genetic studies performed to date in FM have included sizable numbers of older individuals, where the genetic 
contributions to FM or FM symptoms might have been lower or different than in younger cohorts.  
 
Differentiating individuals with primary FM from those with pain from an identifiable source, in a hospital or 
electronic health record (EHR)-based cohort is difficult even with the potentially large arrays of phenotype 
data. Although EHR-based studies can reduce diagnosis/reporting misclassifications and recall bias when 
compared to cohort studies, ongoing sources of nociceptive pain might still be present without a diagnosis and 
hence not identified in an EHR-based study. In particular, nociceptive pain might be relatively more common 
in the population we have considered here, which is based on elective surgery.  How to distinguish between 
pain with or without identifiable causes in such an EHR-based study remains a largely unanswered question. 
This in turn impedes our and other EHR-based studies abilities to isolate the patients with primary FM. 
Johnston et al. 18 in their UK Biobank based study of multi-site chronic pain did not report if individuals have 
identifiable or non-identifiable sources of pain. Given our current measures of FM we cannot definitively say if 
the older individuals we have classified as being FM cases have primary FM or have pain from an identifiable 
source. Thus, we do not have data to speak to if primary FM has a smaller genetic component in older 
individuals than it does in younger individuals.   
Although across age categories females had higher FM scores than males, we do not find evidence that 
heritability varies by sex. This is possible because women can have a higher mean FM score value than men, 
for example because sex-related factors cause higher FM score values in females, but still have the same 
amount of FM score variability explained by genetic variation. We can interpret this as follows: although the 
average FM-scores in females are higher than in men, the genetic contributions to FM score variability do not 
differ significantly by sex in this sample size.
FM co-occurs with multiple diseases, suggesting there are shared genetic factors underlying these diseases. We 
found that FM score and SSI have a strong genetic correlation with several psychiatric and personality 
syndromes indicating a substantial genetic overlap between them, potentially because psychological measures 
are part of the FM score.  However, our genetic correlation findings for FM score are in agreement with results 
from a UK Biobank study (n=387,649) by Johnston et al., that found a genetic overlap between MCP and 
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asthma and rheumatoid arthritis than was MCP from the UK Biobank. For rheumatoid arthritis this may be due 
to an enrichment of individuals with rheumatoid arthritis in our surgical patient population compared to the 
more general UK Biobank population.  
One limitation of our study is that our sample is not population-based. Individuals who were scheduled to have 
surgery were eligible for recruitment in the study and are more likely to suffer from pain and to be enriched for 
particular FM-related disorders. Additionally, we have used quantile-based inverse normalization of FM score 
which can affect the power to detect heritability.
Overall, this study highlights the importance of considering the age distribution of individuals when designing 
a genetic association study of FM. These data support the distinction that there are (at least) two different 
forms of FM: one that occurs in younger individuals and is strongly genetically driven – and the other that 
occurs in older individuals and can be driven by a variety of non-genetic factors and other conditions that cause 
pain.
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 Category (years) N
Estimate (%) SE P-value
≤ 40 5,693 22.8 13.4 0.09
> 40 21,056 8.1 4.9 0.06≤ 50 10,201 23.5 7.9 3.0 x 10-4
> 50 16,548 8.6 5.6 0.12≤ 60 16,687 12.4 5.5 0.01
> 60 10,062 7.5 8.1 0.41
All 26,749 13.9 2.9 1.6 x 10-7


















































(individuals with age ≤ 50)
Genetic Correlation
 (individuals with > 50)
Genetic correlation in 
UK Biobank
Trait PMID
FM WPI SSI FM WPI SSI FM WPI SSI MCP
Depressive Symptoms P 27089181 0.53* 0.11 0.49* 0.63* 0.12 0.59* 0.49* 0.07 0.44* 0.59*
Major Depressive 
disorder P
29700475 0.40* 0.08 0.43* 0.48* 0.07 0.50* 0.36* 0.09 0.37* 0.53*
Bipolar disorder P 21926972 0.08 0.03 0.09 0.13 0.04 0.14* 0.06 0.04 0.07 0.02
Attention deficit 
hyperactivity disorder P
27663945 0.78* 0.19* 0.66* 0.81* 0.20* 0.80* 0.53* 0.15 0.54* Not reported
Subjective Well Being P 27089181 -0.26* -0.12 -0.28* -0.25* -0.11 -0.23* -0.21* -0.14 -0.22* Not reported
PGC Cross disorder 
analysis P
24353885 0.28* 0.15 0.33* 0.32* 0.13 0.34* 0.25* 0.11 0.30* 0.13*
Autism Spectrum 
disorder P
30804558 0.04 -0.01 0.05 -0.01 -0.02 0.04 0.05 0.01 0.07 -0.10*
Anorexia Nervosa P 24514567 -0.09 -0.06 -0.12 -0.13 -0.07 -0.17* -0.07 -0.06 -0.10 -0.06*
Rheumatoid Arthritis A 24390342 0.35* 0.38* 0.26* 0.38* 0.39* 0.25* 0.31* 0.32* 0.19* 0.16*
Asthma A 17611496 0.31* 0.33* 0.30* 0.40* 0.45* 0.39* 0.28* 0.30* 0.22 0.22*
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Table 2: Genetic correlation of FM score, WPI score and SSI score with selected traits for overall sample as well as across age 
categories. Significant (p-value < 0.05) estimates are marked as (*). Superscript index: P = Psychiatric trait; A = immune/autoimmune 
trait; R = Personality trait; S = Sleeping trait. 
Neuroticism R 27089181 0.39* 0.16 0.35* 0.45* 0.17* 0.41* 0.37* 0.13 0.38* 0.40*
Sleep duration S 27494321 -0.03 0.05 -0.11 -0.02 0.01 -0.08 -0.03 0.02 -0.08 Not reported
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Figure legends:
Figure 1: Distribution of FM Scores in the sample included for analysis. The range of FM scores 
is from 0 to 31. A blue vertical line corresponding to the FM-score of 13 shows the cut-off for 
being treated as FM. Any sample having a FM-score above or equal to 13 is clinically considered 
to be an FM patient. 
Figure 2: Distribution of FM scores divided into 10-year age-categories, in (A) the sample and 
also across (B) females and (C) males.
Figure 3: Heritability of FM, WPI and SSI scores by age categories. The vertical axis represents 
the estimated heritability (in percentage) while the horizontal axis represents the different age 
categories from younger to older (left to right) in groups of 10 years. 
Figure 4:  Estimated pairwise genetic correlation matrices between FM, WPI and SSI by age 
categories. Different colors represent different combinations of traits used to estimate the 
genetic correlation. 
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
art_41171_f1.tif
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
art_41171_f2.tif
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
art_41171_f3.tif
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
art_41171_f4.tiff
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
